← Back to Clinical Trials
Recruiting Phase 4 NCT07721714

NCT07721714 SMILE Surgery in One Eye Compared to Ray Tracing-guided LASIK Surgery in the Fellow Eye

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07721714
Status Recruiting
Phase Phase 4
Sponsor Stanford University
Condition Myopia
Study Type INTERVENTIONAL
Enrollment 62 participants
Start Date 2026-08-05
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 22 Years
Max Age 59 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
Ray tracing guided LASIK surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 62 participants in total. It began in 2026-08-05 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Participants will undergo LASIK surgery in one eye using ray tracing guided technology in one eye and LASIK surgery in the other eye using wavefront guided technology. We are comparing outcomes between the two technologies as measured by self reported quality of vision and quality of life outcomes using validated questionnaires before and after surgery. We will also be comparing outcomes between the two technologies including measurement of low contrast visual acuity,and best spectacle corrected visual acuity.

Eligibility Criteria

Inclusion Criteria: Subjects age 22 and older with healthy eyes. Nearsightedness between -1.00 diopters and -8.00 diopters. Subjects with less than or equal to 3.00 diopters of astigmatism. Exclusion Criteria: Subjects under the age of 22. Subjects with excessively thin corneas. Subjects with topographic evidence of keratoconus. Subjects with ectactic eye disorders. Subjects with autoimmune diseases. Subjects who are pregnant or nursing. Subjects must have similar levels of nearsightedness in each eye. They can not be more than 1.5 diopter of difference between eyes. Subjects with more than 3.00 diopters of astigmatism Subjects must have similar levels of astigmatism in each eye. They can not have more than 0.75 diopters of difference between eyes.

Contact & Investigator

Central Contact

Edward E Manche, MD

✉ edward.manche@stanford.edu

📞 1-650-498-7020

Frequently Asked Questions

Who can join the NCT07721714 clinical trial?

This trial is open to participants of all sexes, aged 22 Years or older, up to 59 Years, studying Myopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07721714 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT07721714 currently recruiting?

Yes, NCT07721714 is actively recruiting participants. Contact the research team at edward.manche@stanford.edu for enrollment information.

Where is the NCT07721714 trial being conducted?

This trial is being conducted at Palo Alto, United States.

Who is sponsoring the NCT07721714 clinical trial?

NCT07721714 is sponsored by Stanford University. The trial plans to enroll 62 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology